leisure time -WSS

leisure time

author：fashion 2025-10-01 15:31:46 - browse：78935

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Scientists at the Food and Drug Administration have two big questions about Eli Lilly’s experimental Alzheimer’s drug donanemab ahead of a panel of outside experts that it is convening on Monday:

Should the patients who receive the medicine be limited based on PET scans of a protein called tau that Eli Lilly used as a key criteria for trying to determine whether they should receive the drug? That could reduce usage of the medicine by adding a barrier to its use.

And how do the potential risks of using the drug compare to its benefits? The FDA points to one analysis, admittedly with missing data, that could indicate patients who receive the drug have a higher risk of dying.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： PBMs drew scrutiny in House hearing — and so did pharma

hotspot

WSS

Key Senate committee drafts bipartisan bill to stem drug shortages

Element Biosciences CEO lays out genome sequencing strategy

The struggle to figure out which patients 'deserve' Wegovy

Health care needs a new profession: neuroimaging counseling

Key Senate committee drafts bipartisan bill to stem drug shortages

Diversity in clinical trials starts with building trust, experts say

entertainment

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Anesthesiologist group: stop taking Ozempic before surgery

Why does health care cost so much? A reading guide

Medicare proposal to cover medical devices draws a mixed reaction

UnitedHealth financials solid despite Change Healthcare cyberattack

Tori Bowie and the unacceptable rates of Black maternal death

Dogs on Prozac: What pet anti

How one medical school became remarkably diverse

Eli Lilly CEO gives to Mike Pence presidential super PAC

United colonoscopy coverage change 'may cost lives,' doctors say

Bird flu outbreak in cows is latest avian flu curveball

leisure time

PBMs drew scrutiny in House hearing — and so did pharma

Midwives could help bridge maternal health disparities in the U.S.

Assistant physicians can help address the primary care shortage

Key Senate committee drafts bipartisan bill to stem drug shortages

Assistant physicians can help address the primary care shortage

More tobacco lobbyists active in statehouses

knowledge

leisure time

hotspot

focus